

FIG S5 Epitope mapping of plasma neutralizing antibodies in SCIV-infected RMs. Neutralization curves are shown for early plasma samples (weeks 12 and 24) from four RMs (indicated on the top) that developed low-titer heterologous neutralization breadth (also see Fig. 3). Site-directed mutants of ZM233, 25710 and X2278 Envs (indicated on the right) show that

changes at residues 166, 169 and/or 171 reduce plasma neutralization, indicating that the low-titer heterologous plasma breadth maps to the V2-apex. Corresponding ID_{50} values are shown on the right.